Evolus’ (EOLS) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report report published on Friday, Benzinga reports. The firm currently has a $22.00 target price on the stock.

A number of other brokerages have also weighed in on EOLS. Cantor Fitzgerald reissued an overweight rating on shares of Evolus in a research note on Monday, September 9th. HC Wainwright reissued a buy rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, August 1st.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $17.49 on Friday. The business’s fifty day moving average price is $13.76 and its two-hundred day moving average price is $13.05. The stock has a market cap of $1.10 billion, a PE ratio of -16.66 and a beta of 1.31. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. Evolus has a one year low of $7.44 and a one year high of $17.59.

Evolus (NASDAQ:EOLS) last announced its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. On average, analysts forecast that Evolus will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Several large investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its holdings in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after acquiring an additional 739 shares during the last quarter. ProShare Advisors LLC raised its stake in Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock valued at $162,000 after purchasing an additional 1,035 shares during the period. Arizona State Retirement System raised its stake in Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after purchasing an additional 1,253 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Evolus by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares during the last quarter. Finally, Tradition Wealth Management LLC increased its stake in shares of Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after acquiring an additional 2,475 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.